Shakur Mohibi

608 total citations
21 papers, 413 citations indexed

About

Shakur Mohibi is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shakur Mohibi has authored 21 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 13 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Shakur Mohibi's work include Cancer-related Molecular Pathways (9 papers), Epigenetics and DNA Methylation (7 papers) and RNA Research and Splicing (5 papers). Shakur Mohibi is often cited by papers focused on Cancer-related Molecular Pathways (9 papers), Epigenetics and DNA Methylation (7 papers) and RNA Research and Splicing (5 papers). Shakur Mohibi collaborates with scholars based in United States, China and United Kingdom. Shakur Mohibi's co-authors include Xinbin Chen, Jin Zhang, Sameer Mirza, Vimla Band, Hamid Band, Yanhong Zhang, Min Zhang, Enshun Xu, Yuqian Jiang and Vimla Band and has published in prestigious journals such as Journal of Biological Chemistry, Molecular and Cellular Biology and Oncogene.

In The Last Decade

Shakur Mohibi

20 papers receiving 412 citations

Peers

Shakur Mohibi

ONCOL

GENET

PRM

Maïka Jangal Canada

Daniel Gómez-Cabello Spain

Jana S. Eaton United States

Rosario Machado-Pinilla Spain

Woo Chan Shin South Korea

Ines Oršolić Croatia

Alexandra McMellen United States

Wei Mai China

Guolin Chai China

Hsiao-Ching Chuang United States

Maïka Jangal Canada

Shakur Mohibi

321 ×0.9

82 ×0.7

73 ×0.9

ONCOL

33 ×1.1

GENET

26 ×1.2

PRM

Citations per year, relative to Shakur Mohibi Shakur Mohibi (= 1×) peers Maïka Jangal

Countries citing papers authored by Shakur Mohibi

Since Specialization

Citations

This map shows the geographic impact of Shakur Mohibi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shakur Mohibi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shakur Mohibi more than expected).

Fields of papers citing papers by Shakur Mohibi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shakur Mohibi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shakur Mohibi. The network helps show where Shakur Mohibi may publish in the future.

Co-authorship network of co-authors of Shakur Mohibi

This figure shows the co-authorship network connecting the top 25 collaborators of Shakur Mohibi. A scholar is included among the top collaborators of Shakur Mohibi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shakur Mohibi. Shakur Mohibi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Xinbin, Wenqiang Sun, Yanhong Zhang, et al.. (2025). TAp63γ is the primary isoform of TP63 for tumor suppression but not development. Cell Death Discovery. 11(1). 51–51.

Mohibi, Shakur, et al.. (2024). Ferredoxin 1 is essential for embryonic development and lipid homeostasis. eLife. 13. 8 indexed citations

Zhang, Jin, Hee Jung Yang, Shakur Mohibi, et al.. (2024). Ninjurin 2, a Cell Adhesion Molecule and a Target of p53, Modulates Wild-Type p53 in Growth Suppression and Mutant p53 in Growth Promotion. Cancers. 16(1). 229–229. 1 indexed citations

Zhang, Yanhong, et al.. (2022). Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1–SREBP pathway. Oncogene. 41(12). 1718–1726. 17 indexed citations

Mohibi, Shakur, Mingyi Chen, Xinbin Chen, & Jin Zhang. (2022). Poly zinc finger protein ZFP14 suppresses lymphomagenesis and abnormal inflammatory response via the HOXA gene cluster. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1869(1). 166587–166587. 1 indexed citations

Rabow, Zachary, Tong Shen, Shakur Mohibi, et al.. (2022). p73α1, an Isoform of the p73 Tumor Suppressor, Modulates Lipid Metabolism and Cancer Cell Growth via Stearoyl-CoA Desaturase-1. Cells. 11(16). 2516–2516. 8 indexed citations

Mohibi, Shakur, Xinbin Chen, & Jin Zhang. (2022). ZFP14 Regulates Cancer Cell Growth and Migration by Modulating p53 Protein Stability as Part of the MDM2 E3 Ubiquitin Ligase Complex. Cancers. 14(21). 5226–5226. 4 indexed citations

Mohibi, Shakur, Jin Zhang, Mingyi Chen, & Xinbin Chen. (2021). Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53–Mdm2 Axis. Molecular Cancer Research. 19(10). 1751–1762. 5 indexed citations

Mohibi, Shakur, Jin Zhang, & Xinbin Chen. (2020). PABPN1, a Target of p63, Modulates Keratinocyte Differentiation through Regulation of p63α mRNA Translation. Journal of Investigative Dermatology. 140(11). 2166–2177.e6. 10 indexed citations

10.

Mohibi, Shakur, Xinbin Chen, & Jin Zhang. (2019). Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer. Pharmacology & Therapeutics. 203. 107390–107390. 134 indexed citations

11.

Zhang, Min, Yanhong Zhang, Enshun Xu, et al.. (2018). Rbm24, a target of p53, is necessary for proper expression of p53 and heart development. Cell Death and Differentiation. 25(6). 1118–1130. 68 indexed citations

12.

Mohibi, Shakur, et al.. (2016). Acetylation of Mammalian ADA3 Is Required for Its Functional Roles in Histone Acetylation and Cell Proliferation. Molecular and Cellular Biology. 36(19). 2487–2502. 14 indexed citations

13.

Zhao, Xiangshan, Sameer Mirza, Bhavana J. Davé, et al.. (2016). ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Research. 18(1). 113–113. 10 indexed citations

14.

Mohibi, Shakur, et al.. (2015). Alteration/Deficiency in Activation 3 (ADA3) Protein, a Cell Cycle Regulator, Associates with the Centromere through CENP-B and Regulates Chromosome Segregation. Journal of Biological Chemistry. 290(47). 28299–28310. 11 indexed citations

15.

Mirza, Sameer, Emad A. Rakha, Alaa T. Alshareeda, et al.. (2013). Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. Breast Cancer Research and Treatment. 137(3). 721–731. 14 indexed citations

16.

Zhao, Xiangshan, Sameer Mirza, Alaa T. Alshareeda, et al.. (2012). Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. Breast Cancer Research and Treatment. 134(1). 171–180. 21 indexed citations

17.

Mirza, Sameer, Rakesh Kumar, Jun Wang, et al.. (2012). Alteration/deficiency in activation-3 (Ada3) plays a critical role in maintaining genomic stability. Cell Cycle. 11(22). 4266–4274. 17 indexed citations

18.

Mohibi, Shakur, Channabasavaiah B. Gurumurthy, Alo Nag, et al.. (2012). Mammalian Alteration/Deficiency in Activation 3 (Ada3) Is Essential for Embryonic Development and Cell Cycle Progression. Journal of Biological Chemistry. 287(35). 29442–29456. 23 indexed citations

19.

Band, Vimla, et al.. (2011). Mouse models of estrogen receptor-positive breast cancer. Journal of Carcinogenesis. 10(1). 35–35. 31 indexed citations

20.

Zhao, Xiangshan, Channabasavaiah B. Gurumurthy, Gautam Malhotra, et al.. (2011). Breast Cancer Subtypes: Two Decades of Journey from Cell Culture to Patients. Advances in experimental medicine and biology. 720. 135–144. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact